Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion

Asian Journal of Andrology

Volumn 16, Issue 2, 2014, Pages 319-324

  Sun, Yi ^a   Wei, Min ^a,b   Ren, Shan Cheng ^a   Chen, Rui ^a   Xu, Wei Dong ^a   Wang, Fu Bo ^a   Lu, Ji ^a   Shen, Jian ^a   Yu, Yong Wei ^a   Hou, Jian Guo ^a   Xu, Chuan Liang ^a   Huang, Jiao Ti ^c   Sun, Ying Hao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epigenomics; Histone methyltransferases; Prostate cancer (PCa); SETDB1

Indexed keywords

HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE SETDB1; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; CELL COUNTING; CELL CYCLE ASSAY; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; EPITHELIUM CELL; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BASE SEQUENCE; CELL CYCLE; DNA PRIMERS; GENE SILENCING; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTEIN METHYLTRANSFERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84896794089     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.122812     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 2012;62: 283-98.
2. Roberts WB, Han M. Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surg Oncol 2009;18: 268-74.
3. Saad F, Hotte S, North S, Eigl B, Chi K, et al. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Research 2011;17: 5765-73.
4. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, et al. Gene expression analysis of prostate cancers. Mol Carcinog 2002;33: 25-35. (Pubitemid 34052304)
5. Yu YP, Song C, Tseng G, Ren BG, LaFramboise W, et al. Genome abnormalities precede prostate cancer and predict clinical relapse. Am J Pathol 2012;180: 2240-8.
6. Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009;150: 3991-4002.
7. Jeronimo C, Henrique R. Epigenetic biomarkers in urological tumors: a systematic review. Cancer Lett 2011.
8. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007;128: 707-19. (Pubitemid 46273570)
9. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Bio 2007;8: 307-18. (Pubitemid 46474659)
10. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10: 295-304.
11. Kouzarides T. Chromatin modifications and their function. Cell 2007;128: 693-705. (Pubitemid 46273577)
12. Rando OJ, Chang HY. Genome-wide views of chromatin structure. Annu Rev Biochem 2009;78: 245-71.
13. McKinsey TA, Zhang CL, Olson EN. Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev 2001;11: 497-504. (Pubitemid 32800722)
14. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ 3rd. SETDB1: A novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev 2002;16: 919-32. (Pubitemid 34408542)
15. Harte PJ, Wu W, Carrasquillo MM, Matera AG. Assignment of a novel bifurcated SET domain gene, SETDB1, to human chromosome band 1q21 by in situ hybridization and radiation hybrids. Cytogenet Cell Genet 1999;84: 83-6. (Pubitemid 29218934)
16. Macgregor S, Montgomery GW, Liu JZ, Zhao ZZ, Henders AK, et al. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet 2011;43: 1114-8.
17. Rodriguez-Paredes M, Martinez de Paz A, Simo-Riudalbas L, Sayols S, Moutinho C, et al. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene 2013.
18. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011;471: 513-7.
19. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007;2: 329-33. (Pubitemid 47040047)
20. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003;63: 1727-30. (Pubitemid 36460827)
21. Garcia SB, Park HS, Novelli M, Wright NA. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J Pathol 1999;187: 61-81. (Pubitemid 29009836)
22. Hu M, Yao J, Cai L, Bachman KE, van den Brule F, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005;37: 899-905. (Pubitemid 41077119)
23. Yang L, Xia L, Wu DY, Wang H, Chansky HA, et al. Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene 2002;21: 148-52. (Pubitemid 34076387)
24. Binda O, LeRoy G, Bua DJ, Garcia BA, Gozani O, et al. Trimethylation of histone H3 lysine 4 impairs methylation of histone H3 lysine 9: Regulation of lysine methyltransferases by physical interaction with their substrates. Epigenetics 2010;5: 767-75.
25. Albert M, Helin K. Histone methyltransferases in cancer. Semin Cell Dev Biol 2010;21: 209-20.
26. Schneider R, Bannister AJ, Kouzarides T. Unsafe SETs: Histone lysine methyltransferases and cancer. Trends Biochem Sci 2002;27: 396-402. (Pubitemid 34874749)
27. Morishita M, di Luccio E. Cancers and the NSD family of histone lysine methyltransferases. Biochim Biophys Acta 2011;1816: 158-63.
28. Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci U S A 2006;103: 19176-81. (Pubitemid 350002846)
29. Gong Y, Huo L, Liu P, Sneige N, Sun X, et al. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 2011;117: 5476-84.
30. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322: 1695-9.
31. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 2009;106: 5324-9.